Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Marber

Showing results (1-10 of 94) with videos related to

Pageof 10
Sort By:
Journal of the American College of Cardiology|March 1, 2002
Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospectsMetin Avkiran, Michael S Marber
Experimental and Clinical Cardiology|August 4, 2009
Factors determining heterogeneity in coronary collateral development: A clinical perspectivePier D Lambiase, Michael S Marber
Journal of Pharmacological and Toxicological Methods|February 28, 2004
An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heartSimon G Fisher, Michael S Marber
Experimental Physiology|October 16, 2012
Advancements in pressure-volume catheter technology - stress remodelling after infarctionJames E Clark, Michael S Marber
Journal of Molecular and Cellular Cardiology|November 11, 2010
The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failureMichael S Marber, Beth Rose, Yibin Wang
Drug Discovery Today. Disease Mechanisms|February 1, 2011
Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in pointMichael S Marber, Jeffery D Molkentin, Thomas Force
Biochemical Pharmacology|October 13, 2004
Specificity of action of bisindolylmaleimide protein kinase C inhibitors: do they inhibit the 70kDa ribosomal S6 kinase in cardiac myocytes?Neil A Roberts, Michael S Marber, Metin Avkiran
Pharmacology & Therapeutics|September 4, 2007
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart diseaseJames E Clark, Negin Sarafraz, Michael S Marber
Current Opinion in Pharmacology|February 22, 2008
Targeting p38-MAPK in the ischaemic heart: kill or cure?Rekha Bassi, Richard Heads, Michael S Marber, et al.
Heart (British Cardiac Society)|January 4, 2011
Troponins: redefining their limitsJames O Baker, Johannes Reinhold, Simon Redwood, et al.
Pageof 10

Showing results (1-10 of 94) with videos related to

Sort By:
Pageof 10
Journal of the American College of Cardiology|March 1, 2002
Na(+)/H(+) exchange inhibitors for cardioprotective therapy: progress, problems and prospectsMetin Avkiran, Michael S Marber
Experimental and Clinical Cardiology|August 4, 2009
Factors determining heterogeneity in coronary collateral development: A clinical perspectivePier D Lambiase, Michael S Marber
Journal of Pharmacological and Toxicological Methods|February 28, 2004
An in vivo model of ischaemia-reperfusion injury and ischaemic preconditioning in the mouse heartSimon G Fisher, Michael S Marber
Experimental Physiology|October 16, 2012
Advancements in pressure-volume catheter technology - stress remodelling after infarctionJames E Clark, Michael S Marber
Journal of Molecular and Cellular Cardiology|November 11, 2010
The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failureMichael S Marber, Beth Rose, Yibin Wang
Drug Discovery Today. Disease Mechanisms|February 1, 2011
Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in pointMichael S Marber, Jeffery D Molkentin, Thomas Force
Biochemical Pharmacology|October 13, 2004
Specificity of action of bisindolylmaleimide protein kinase C inhibitors: do they inhibit the 70kDa ribosomal S6 kinase in cardiac myocytes?Neil A Roberts, Michael S Marber, Metin Avkiran
Pharmacology & Therapeutics|September 4, 2007
Potential of p38-MAPK inhibitors in the treatment of ischaemic heart diseaseJames E Clark, Negin Sarafraz, Michael S Marber
Current Opinion in Pharmacology|February 22, 2008
Targeting p38-MAPK in the ischaemic heart: kill or cure?Rekha Bassi, Richard Heads, Michael S Marber, et al.
Heart (British Cardiac Society)|January 4, 2011
Troponins: redefining their limitsJames O Baker, Johannes Reinhold, Simon Redwood, et al.
Pageof 10